News | Hemodynamic Support Devices | June 20, 2017

FDA Announces Recall of Maquet Intra-aortic Balloon Pumps

IABP recall for Maquet, Datascope intra-aortic balloon pump CS100 and CS300

June 20, 2017 — The U.S. Food and Drug Administration (FDA) said Maquet/Datascope is voluntarily performing a worldwide field correction of certain intra-aortic balloon pumps (IABPs) for a potential electrical test failure code. This field correction also applies to any System 98 or System 98XT IABP that was converted to a CS100i or CS300 IABP.

Datascope received a complaint that has been associated with a patient death due to the failure of the device to initiate therapy. This complaint involved a CS300 IABP that did not pump due to an electrical test failure code #58 (power up vent tests fail), maintenance code #3, and an autofill failure. An electrical test failure code #58 is caused by a solenoid valve requiring more power than the solenoid driver board can deliver to open the valve.

Patients receiving IABP therapy are in critical condition and sudden interruption of therapy could result in unsafe, hemodynamic instability.

The affected IABP units were distributed in the U.S. and worldwide (in over 100 countries). Affected units were distributed between March 23, 2003, and Dec. 11, 2013. Units distributed after Dec. 11, 2013, are not affected by the field correction. There are approximately 12,000 affected units sold globally.

Maquet has told end-users that the risk-benefit of using an affected CS100i, CS100 or CS300 IABP should be assessed by the medical team for each patient when no alternative IABP or alternative therapy is available. The company said clinicians should not leave the patient unattended during IABP therapy.

An additional hazard associated with a sudden shutdown is related to the static condition (no inflating or deflating) of the balloon during the interruption of therapy, the vendor said. The patient balloon should not remain inactive in the patient (i.e., not inflating or deflating) for more than 30 minutes due to the potential for thrombus formation.

Until the service is performed, Datascope recommends powering on the IABP prior to inserting the IAB catheter to allow the IABP to successfully complete its self-test. This action will take less than 60 seconds to perform. In the event the IABP fails to successfully complete the self-test and exhibits electrical test failure code 58, please remove the IABP from service and contact your local Maquet/Getinge sales and service office.
A service representative from Datascope will be replacing the defective solenoid driver boards. Customers having affected IABP unit(s) will be contacted by a representative of the Maquet/Getinge service team to schedule on-site service.

For additional information regarding this field correction, contact the customer service department at 1-888-627-8383 and press 2 (Monday through Friday from 8 a.m. to 6 p.m. EDT).

 

Related Content:

FDA Clears Teleflex Arrow AC3 Optimus Intra-Aortic Balloon Pump (IABP)

Improving Cardiogenic Shock Survival With New Protocols

Peer-Reviewed Publication Shows Larger Capacity IABP Have Greater Hemodynamic Effect on Patients

Teleflex Announces Worldwide Recall of Arrow IAB Catheter and Percutaneous Insertion Kits
 

For more information: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm563615.htm


Related Content

News | Hemodynamic Support Devices

October 23, 2023 — Supira Medical, Inc., a Shifamed portfolio company, announced that the company's percutaneous ...

Home October 23, 2023
Home
News | Hemodynamic Support Devices

November 1, 2022 — Abiomed announced that Impella RP Flex with SmartAssist has received U.S. Food and Drug ...

Home November 01, 2022
Home
News | Hemodynamic Support Devices

September 17, 2022 — Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To ...

Home September 17, 2022
Home
News | Hemodynamic Support Devices

November 12, 2020 — Abiomed recently announced new PROTECT III study data that demonstrates reduced rates of MACCE ...

Home November 12, 2020
Home
Videos | Hemodynamic Support Devices

Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the ...

Home October 20, 2020
Home
News | Hemodynamic Support Devices

October 16, 2020 — The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more ...

Home October 16, 2020
Home
News | Hemodynamic Support Devices

July 16, 2020 – The U.S. Food and Drug Administration (FDA) approved one-way digital data streaming during patient ...

Home July 16, 2020
Home
News | Hemodynamic Support Devices

June 5, 2020 — Abiomed announced the U.S. Food and Drug Administration (FDA) has approved the company's investigational ...

Home June 05, 2020
Home
Videos | Hemodynamic Support Devices

This is a quick animation demonstrating how the new 9 French Abiomed Impella ECP expands to approximately 18 French and ...

Home June 05, 2020
Home
Subscribe Now